207. ASCO 2026 - Agents of the Future - Part 2
About this episode
The episode discusses promising cancer trials and orphan status cancers as part of ASCO 2026 coverage.
This week, Josh and Michael's ASCO 2026 coverage looks at "Agents of the Future", trials of intrigue, promise and potential beyond its status. This episode also sheds light on more orphan status cancers like head and neck cancer, basket cohort studies, resistant EGFR lung cancer, metastatic colorectal cancer and hepatocellular carcinoma. One more episode left of this arc - The Plenary! Stay tuned. Studies Discussed in this Episode OrigAMI-4 WU-KONG28 A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), In Patients with Unresectable Locally Advanced or Metastatic Cancer ESANOA ROSETTA Lung-02 Ivonescimab + FOLFOX HERIZON-CRC01 CIRCULATE EMERALD-3 BLUESTAR GLP-1 agonist in breast cancer (Palleschi et al) For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with…
Sponsors
Pfizer, Merck Pharmaceuticals
More episodes of Oncology for the Inquisitive Mind
- 208. ASCO 2026 - The Plenary Episode - Part 3
- 206. ASCO 2026 - Part 1
- 205. ESTRO update with A/Prof Steven David
Explore listener stats, chart rankings, contacts and more on the Oncology for the Inquisitive Mind podcast page.